Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FIRST: Mankind Pharma...

    FIRST: Mankind Pharma unveils infertility drug Dydrogesterone in India

    Farhat NasimWritten by Farhat Nasim Published On 2019-12-06T11:04:46+05:30  |  Updated On 6 Dec 2019 11:04 AM IST
    FIRST: Mankind Pharma unveils infertility drug Dydrogesterone in India

    With the launch of generic Dydrogesterone tablets, Mankind Pharma has become the first Indian and second global firm to develop the drug for the treatment of infertility and pregnancy-related complications.


    New Delhi: Drug firm Mankind Pharma on Thursday said it has launched its generic Dydrogesterone tablets for the treatment of infertility and pregnancy-related complications in the Indian market. With the launch, the company has become the first Indian and second global firm to develop the drug, Mankind Pharma said in a statement.


    The company's product is a generic version of Abbott's Duphaston tablets, it added.


    The manufacturing process of Dydrogesterone is very complex as it involves the conversion of natural progesterone, the statement said.


    Progesterone is a natural hormone involved in a menstrual cycle, implantation and in successful maintenance of pregnancy.


    Any deficiency of progesterone during different stages of the reproductive process can cause infertility, menstrual disorders and miscarriage, it added.


    Also Read: Delhi HC restricts Lee Pharma from infringing copyright of Mankind Pharma


    "The launch of this drug is an important milestone for Mankind Pharma. We are the first Indian pharmaceutical company to develop this drug and second company in the world," Mankind Group founder and Chairman R C Juneja said.


    Currently, the drug is being launched only in India post that the company is planning to launch the drug in countries where it already has a presence, he added.


    Mankind has a strong presence in pharmaceutical, veterinary, OTC & FMCG segments. The company is present across North America, Asia, Africa and CIS countries.


    Also Read: Mankind Pharma faces setback: Government prohibits Buclizine as an Apetite Stimulant

    AbbottDuphastondydrogesteroneFMCGgenericIndiainfertilityMankindMankind PharmamenstrualOTCpregnancypregnancy complicationsProgesteroneveterinary
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok